This article is more than 5 years old. Information may no longer be current.

Catch up on OSN’s top stories of the week

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are some of the leading stories on Healio.com/OSN in the past week:

Unused drugs impact cost, environment

When unused pharmaceuticals associated with phacoemulsification were measured at four surgical sites, the estimated annual cost of the wasted products reached approximately $195,200 per site. Read more.

FDA rejects Kala’s dry eye NDA, requests additional data

A complete response letter from the FDA regarding the company’s new drug application indicated that efficacy data from an additional trial will be necessary to support a resubmission. Read more.

CHMP recommends Lucentis approval for ROP in Europe

Lucentis has been recommended for approval for the treatment of retinopathy of prematurity in preterm infants by the European Medicines Agency’s Committee for Medicinal Products for Human Use. Read more.

Glaukos to acquire Avedro in all-stock transaction

The all-stock transaction is subject to Avedro stockholder approval, as well as customary closing and regulatory approvals, and is expected to be completed by the end of the year. Read more.

SilkTech completes enrollment in trial of biological dry eye treatment candidate

The randomized, double-masked, vehicle-controlled, multicenter trial is evaluating the safety and efficacy of SDP-4 at 0.1%, 1% and 3% concentrations in 305 patients at 25 U.S. sites. Read more.